China Life Insurance Company Limited
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsChina Life Insurance Co Ltd is a leading life insurance provider in China, offering a range of annuity, whole life, and participating insurance products.
What they do
The company primarily operates in the life insurance sector, providing individual and group life insurance, annuities, and accident and health insurance. It offers participating, universal life, and investment-linked products, and invests premiums in fixed income and equity securities. The company also manages assets for third parties through structured entities.
Revenue drivers
- Annuity products — Products like Xin Xiang Zhi Zun Annuity and Xin Ru Yi Annuity generate premiums and fee income, with payments tied to survival and maturity benefits.
- Whole life insurance — Kang Ning Whole Life provides death, disability, and critical illness benefits, with premiums paid regularly or as single payments.
- Participating endowment — Hong Ying Participating Endowment and Fu Lu Shuang Xi Participating Endowment offer maturity and death benefits, with survival payouts every two years in some cases.
- Investment income — The company earns investment income from premiums, including dividends and interest from securities, but incurred impairment charges on available-for-sale securities.
Recent performance
In 2022, the company recognized an impairment charge of RMB2,645 million on its investment in Sino-Ocean, following a cumulative impairment loss of RMB3,217 million as of December 31, 2021. Changes in morbidity rate assumptions increased insurance contract liabilities by RMB2,415 million in 2022, down from RMB5,897 million in 2021. The company received cash dividends from China Unicom and CGB in 2022. Impairment charges on available-for-sale stock securities were RMB15,486 million in 2022, compared to RMB21,354 million in 2021.
Strategy
The company focuses on product innovation in annuities and whole life insurance, with features like critical illness benefits and premium exemptions. It manages investment risks through diversification across real estate, logistics, and other industries via structured entities. The company complies with China's solvency regulations and monitors assumptions such as morbidity rates. It seeks to generate investment income from dividends and interest while managing impairments.
Risks
- Investment concentration risk — The company has significant exposure to Sino-Ocean, with impairment charges of RMB2,645 million in 2022, and a 10% share price decrease could increase impairment by RMB219 million.
- Morbidity rate assumption risk — Changes in morbidity rate assumptions increased insurance contract liabilities by RMB2,415 million in 2022, reflecting updated experience and future expectations.
- Impairment risk on available-for-sale securities — The company recognized an impairment charge of RMB15,486 million on available-for-sale stock securities in 2022, indicating volatility in investment values.
- Interest rate and market risk — Negative interest rates in foreign currencies (e.g., USD LIBOR, EURIBOR) may affect investment returns, with floors applied as per contract terms.
Outlook
Management has not provided specific guidance, but the company continues to manage insurance contract liabilities and investment risks. The outlook depends on morbidity rate assumptions and market conditions affecting investment valuations. The company remains focused on its core insurance operations and investment portfolio.